Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer enhanced targeting of …
Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executives said would …
For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat …
Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive …
Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form …
Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to …
Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug …
Dive Brief: Novartis has suspended production of two cancer drugs at plants in Italy and New Jersey due to “potential quality issues” it identified in …
Cancer Research UK, the world’s largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach to driving …
Dive Brief: Regeneron has agreed to purchase a young biotechnology company for access to a drug that the buyer believes will be a valuable component …
Dive Brief: Seagen, the largest biotechnology company in the Seattle area, has unveiled plans for a manufacturing facility to help provide “greater control and flexibility” …
The Food and Drug Administration appears ready to raise its approval standards for a well-known class of cancer drugs due to concerns they aren’t helping …
GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp …
Each year, the American Association for Cancer Research’s conference spotlights promising early research into new approaches for attacking tumors. This year’s meeting, held in person …
Dive Brief: The Food and Drug Administration has cleared Gilead to restart some trials testing an experimental cancer drug the company acquired in a roughly …
Dive Brief: The Food and Drug Administration has approved the first drug to treat an ultra-rare cluster of conditions caused by mutations in a specific …
Dive Brief: A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for …
An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed …
Dive Brief: Karyopharm Therapeutics will have to perform a new clinical trial to widen the use of its cancer drug selinexor after U.S. regulators said …
Dive Brief: AstraZeneca and Daiichi Sankyo’s antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 study …
